The Cameron lab investigates how non-neuronal astrocytes contribute to the development and progression of glaucoma and other neurodegenerative disorders affecting the retina and optic nerve. This process, in which astrocytes undergo functional changes that can both benefit and harm neuronal health, is known as reactive astrogliosis (or simply reactivity). The dual nature of astrocyte reactivity raises important questions about the factors that regulate reactive astrocyte functions and their effects on neural degeneration and repair. To address this, the lab utilizes a combination of experimental disease models, transgenic alleles, and multi-omic approaches to elucidate the cellular, molecular, and transcriptional mechanisms that underlie reactive astrocyte specification, diversity, and signaling. This understanding guides the development of novel therapeutic strategies to mitigate or even reverse degenerative processes. Uniquely, the lab employs a pioneering adeno-associated virus (AAV) vector approach to deliver candidate gene therapies directly to optic nerve head astrocytes, enabling for the first time, the ability to target the reactive astrocyte population hypothesized to drive glaucomatous disease progression. The ultimate goal of the lab is to translate basic discoveries in astrocyte biology into targeted therapies for clinical application.
Evan Cameron, PhD, is an Assistant Staff member in the Department of Ophthalmic Research. His research program aims to characterize reactive astrocyte functions in the diseased retina, with the goal of developing novel astrocyte-targeted gene therapies to prevent and reverse vision loss associated with glaucoma and other optic neuropathies.
Education & Training
Professional Appointments
Honors & Awards
Memberships
We recently discovered that compartmented nuclear and cytoplasmic cyclic adenosine monophosphate (cAMP) in optic nerve head astrocytes differentially regulates neuroprotective versus neurotoxic astrocyte functions. Currently, the lab is seeking to molecularly and transcriptionally link compartmented cAMP signaling to specific reactive astrocyte functions in an experimental model of glaucoma. The lab is also developing novel gene therapy vectors to target unique reactive astrocyte populations and promote neuroprotective astrocyte reactivity in the retina and optic nerve.
View publications for Evan Cameron, PhD
(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Selected publications:
We are looking for motivated individuals who share our enthusiasm for science and discovery. Individuals of all backgrounds are welcome to apply, but especially those who will thrive in a cohesive and collaborative collegial environment that fosters scientific curiosity, rigor and growth.
Prospective postdocs should email Dr. Evan Cameron ([email protected]) their CV, a brief description (<one page) of their research interests and career goals and contact information for three references.
Interested graduate students should email Dr. Evan Cameron ([email protected]) to discuss potential projects.
Come join our team and enjoy all that the Cole Eye Institute, Lerner Research Institute, Cleveland Clinic Foundation, and the city of Cleveland have to offer!
Our education and training programs offer hands-on experience at one of the nationʼs top hospitals. Travel, publish in high impact journals and collaborate with investigators to solve real-world biomedical research questions.
Learn More